Search Results - "Backes, F. J."

The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role by Smith, B, Neff, R, Cohn, D.E, Backes, F.J, Suarez, A.A, Mutch, D.G, Rush, C.M, Walker, C.J, Goodfellow, P.J

“…Abstract Background Forkhead box protein A2 (FOXA2) plays an important in development, cellular metabolism and tumorigenesis. The Cancer Genome Atlas (TCGA)…”
Get full text

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer by Nagel, C.I, Backes, F.J, Hade, E.M, Cohn, D.E, Eisenhauer, E.L, O'Malley, D.M, Fowler, J.M, Copeland, L.J, Salani, R

“…Abstract Introduction Hematologic, gastrointestinal, and neurologic complications are common side effects of the platinum and taxane-based chemotherapy used in…”
Get full text

Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat? by Backes, F.J., Felix, A.S., Plante, M., Grégoire, J., Sullivan, S.A., Rossi, E.C., Tanner, E.J., Stewart, K.I., Soliman, P.T., Holloway, R.W., Abu-Rustum, N.R., Leitao, M.M.

“…To assess associations between treatment and recurrence-free survival (RFS) among patients with isolated tumor cells (ITCs) in sentinel lymph nodes (SLN) and…”
Get full text

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study by Hamilton, C.A., Miller, A., Casablanca, Y., Horowitz, N.S., Rungruang, B., Krivak, T.C., Richard, S.D., Rodriguez, N., Birrer, M.J., Backes, F.J., Geller, M.A., Quinn, M., Goodheart, M.J., Mutch, D.G., Kavanagh, J.J., Maxwell, G.L., Bookman, M.A.

“…•Of 3010 evaluable patients in GOG 182, 6.5% achieved long term survival (LTS) with survival >10years.•Patients requiring lower complexity surgery and those…”
Get full text

The effect of preoperative nutritional status on postoperative complications and overall survival in patients undergoing pelvic exenteration: A multi-disciplinary, multi-institutional cohort study by Lyell, N.J., Kitano, M., Smith, B., Gleisner, A.L., Backes, F.J., Cheng, G., McCarter, M.D., Abdel-Misih, S., Jones, E.L.

“…Optimization of preoperative nutritional status has been recommended and associated with improved outcomes for other oncologic procedures, but has not been…”
Get full text

Influence of tumor size on outcomes following pelvic exenteration by Smith, B., Jones, E.L., Kitano, M., Gleisner, A.L., Lyell, N.J., Cheng, G., McCarter, M.D., Abdel-Misih, S., Backes, F.J.

“…Pelvic exenteration (PE) is often the only curative option for locally advanced or recurrent pelvic malignancies. Despite radical surgery, recurrence risk and…”
Get full text

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? by Richardson, D.L, Backes, F.J, Hurt, J.D, Seamon, L.G, Copeland, L.J, Fowler, J.M, Cohn, D.E, O'Malley, D.M

“…Abstract Background. Increased rates of bowel perforation in patients with recurrent epithelial ovarian cancer (EOC) treated with bevacizumab have been…”
Get full text

Performance of PREMM 1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases by Mercado, R C, Hampel, H, Kastrinos, F, Steyerberg, E, Balmana, J, Stoffel, E, Cohn, DE, Backes, F J, Hopper, J L, Jenkins, MA, Lindor, N M, Casey, G, Haile, R, Madhavan, S

“…Purpose: Lynch syndrome accounts for 2-5% of endometrial cancer cases. Lynch syndrome prediction models have not been evaluated among endometrial cancer cases…”
Get full text

Performance of PREMM 1,2,6 , MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases by Mercado, R. C., Hampel, H., Mopala, R., Kastrinos, F., Steyerberg, E. W., Balmaña, J., Cohn, D. E., Backes, F. J., De La Chapelle, A., Syngal, S.

“…Abstract only…”
Get full text

Does repeat usage of bevacizumab in patients with progressive recurrent ovarian cancer offer a survival advantage? by Richardson, D. L., Backes, F. J., Seamon, L. G., Hurt, J. D., Cohn, D. E., Fowler, J. M., Copeland, L. J., O'Malley, D. M.

“…Abstract only e16510 Background: Many studies show bevacizumab (BEV) has activity in the treatment of recurrent ovarian cancer, especially when combined with…”
Get full text